Evidence map›Paper›PMID 40422262›Full record

ArticlemBio2025

Targeting the MEK1/2 pathway to combat

Eryn Zuiker, Gregory Serpa, Mithu De, Yiwei Liu, Daniel J Wozniak, Kymberly M Gowdy, Jean Charron, Susan E Birket, Megan R Kiedrowski, Emily A Hemann and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Microbial and host innate immune factors affecting the persistence ofFrontiers in cellular and infection microbiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Eryn ZuikerDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Gregory SerpaDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Mithu DeDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Yiwei LiuDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Daniel J WozniakDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Kymberly M GowdyDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Jean CharronCentre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval (Oncology Axis), Quebec City, Quebec, Canada.
Susan E BirketDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0002-6353-6596
Megan R KiedrowskiDivision of Pulmonary, Allergy, and Critical Care, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Emily A HemannDepartment of Microbial Infection and Immunity, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Matthew E LongDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.ORCID 0000-0003-4485-019X

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
Cooperation and antagonism in polymicrobial infectionR01AI186380 · NIAID · OHIO STATE UNIVERSITY · PI MATTHEW R. PARSEK, Daniel J Wozniak · 2024 to 2026
$2.2M
CTSA Predoctoral T32 at the Ohio State UniversityT32TR004543 · NCATS · OHIO STATE UNIVERSITY · PI GINNY L BUMGARDNER · 2023 to 2026
$1.2M
Cystic Fibrosis Foundation (CFF) LONG19F5-CICystic Fibrosis Foundation (CFF) LONG21R3Cystic Fibrosis Foundation (CFF) MCCOY19R0HHS | National Institutes of Health (NIH) T32TR004543NCATS NIH HHS T32 TR004543NCATS NIH HHS UL1 TR002733NCI NIH HHS P30 CA016058NIAID NIH HHS R01 AI186380
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Bacterial AgentsCystic FibrosisInflammationMAP Kinase Kinase 1MAP Kinase Kinase 2Staphylococcal InfectionsStaphylococcus aureusAnimalsAnti-Inflammatory AgentsDisease Models, AnimalHumansMiceAnti-Bacterial AgentsAnti-Inflammatory AgentsMAP2K2 protein, humanMAP Kinase Kinase 1MAP Kinase Kinase 2cystic fibrosismacrophagesMEK1/2Staphylococcus aureus

Identifiers

PMID40422262
PMCPMC12239583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.